Search hospitals > California > Beverly Hills
Retina-Vitreous Associates Medical Group
Claim this profileBeverly Hills, California 90211
Global Leader in Age-Related Macular Degeneration
Global Leader in Macular Edema
Conducts research for Swelling
Conducts research for Diabetic Macular Edema
Conducts research for Atrophy
116 reported clinical trials
2 medical researchers
Summary
Retina-Vitreous Associates Medical Group is a medical facility located in Beverly Hills, California. This center is recognized for care of Age-Related Macular Degeneration, Macular Edema, Swelling, Diabetic Macular Edema, Atrophy and other specialties. Retina-Vitreous Associates Medical Group is involved with conducting 116 clinical trials across 49 conditions. There are 2 research doctors associated with this hospital, such as David Liao, MD, PhD and Beverly Hills Site PI.Area of expertise
1Age-Related Macular Degeneration
Global LeaderStage I
Stage II
CFI rare variant positive
2Macular Edema
Global LeaderVEGF
Top PIs
David Liao, MD, PhDRetina-Vitreous Associates Medical Group2 years of reported clinical research
Studies Retinitis
Studies Retinitis Pigmentosa
2 reported clinical trials
2 drugs studied
Beverly Hills Site PIBeverly Hills Location3 years of reported clinical research
Studies Choroidal Effusions
Studies Retinal Disease
1 reported clinical trial
1 drug studied
Clinical Trials running at Retina-Vitreous Associates Medical Group
Age-Related Macular Degeneration
Macular Edema
Diabetic Retinopathy
Swelling
Convergence Insufficiency
Atrophy
Retinal Disease
Diabetic Macular Edema
Eye Diseases
Retinal Degeneration
PDS Implant with Ranibizumab
for Age-Related Macular Degeneration
This study is evaluating whether a drug delivery system may help treat age-related macular degeneration.
Recruiting2 awards Phase 33 criteria
RGX-314 Gene Therapy
for Age-Related Macular Degeneration
RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to 12 weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. RGX-314 is being developed as a potential one-time treatment for wet AMD.
Recruiting2 awards Phase 32 criteria
AVD-104
for Age-Related Macular Degeneration
Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
Recruiting1 award Phase 26 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Retina-Vitreous Associates Medical Group?
Retina-Vitreous Associates Medical Group is a medical facility located in Beverly Hills, California. This center is recognized for care of Age-Related Macular Degeneration, Macular Edema, Swelling, Diabetic Macular Edema, Atrophy and other specialties. Retina-Vitreous Associates Medical Group is involved with conducting 116 clinical trials across 49 conditions. There are 2 research doctors associated with this hospital, such as David Liao, MD, PhD and Beverly Hills Site PI.